following a full submission
sitagliptin (Januvia®) is accepted for use within NHS Scotland.
Indication under review: the treatment of type 2 diabetes mellitus to improve glycaemic control in adults as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.
Sitagliptin, compared with placebo, improved glycaemic control in adults with type 2 diabetes mellitus who had inadequate glycaemic control on an insulin-containing regimen.
SMC has previously accepted sitagliptin for use in combination with a sulfonylurea (with or without metformin), and for restricted use with metformin and as monotherapy. This now extends the advice to include its use in combination with insulin.
Download detailed advice164KB (PDF)
Medicine details
- Medicine name:
- sitagliptin (Januvia)
- SMC ID:
- 1083/15
- Indication:
- The treatment of type 2 diabetes mellitus to improve glycaemic control in adults as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control
- Pharmaceutical company
- MSD
- BNF chapter
- Endocrine system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 07 September 2015